As part of our year in review, we’re sharing some results from studies that have been done. Glu was used to query patients about injectable glucagon, as part of a study sponsored by an emerging biotech partner interested in improving usability of injectable glucagon through alternative modes of administration. In only ten days data were collected from 126 respondents. Findings were shared with the United States Food and Drug Administration (FDA) to illustrate the shortcomings in current modes of glucagon administration.
By participating on Glu, you're helping researchers develop innovative treatments and devices that people with type 1 diabetes really need and want. Help us continue to amplify your voice. Support our work today!